Calico Biosystems

Calico Biosystems is a Swiss biotechnology company that provides a New Approach Methodology (NAM) platform for oncology drug development. Its platform utilizes intact patient tumor samples to test drug efficacy directly, moving away from artificial models like cell lines or organoids to provide clinically relevant data. The company integrates multi-omics assays on native tumors with advanced algorithmic modeling, known as CaliPower, to quantify target expression, identify promising therapeutic combinations, and generate mechanistic insights. By using these human biology-based data, the platform aims to accelerate the preclinical-to-clinical transition and improve the predictive accuracy of oncology trials.

The company's services are designed to help pharmaceutical and biotechnology partners de-risk their drug development pipelines, optimize clinical trial design, and improve patient stratification. By identifying the most effective treatment combinations and high-value indications, Calico Biosystems assists in reducing high attrition rates and development costs for anti-cancer therapeutics. Headquartered in Crissier, Switzerland, the company was founded in 2023 by Dr. Marie-Agnès Doucey and Dr. Riccardo Turrini, leveraging over 15 years of scientific and leadership experience in oncology and systems immunology. It has received funding and recognition from programs such as Venture Kick and has established strategic partnerships to scale its predictive drug development capabilities globally.